Gimeracil/oteracil/tegafur/folinic acid

Drug Profile

Gimeracil/oteracil/tegafur/folinic acid

Alternative Names: Folinic acid/S-1; Gimeracil/oteracil potassium/tegafur/calcium folinate; Gimeracil/oteracil potassium/tegafur/folinic acid; Gimeracil/oteracil/tegafur/calcium folinate; Gimeracil/oteracil/tegafur/leucovorin; S-1/folinic acid; TAS 118

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics; Chemoprotectants; Chemosensitisers; Formyltetrahydrofolates; Furans; Pyridines; Pyrimidinones; Small molecules; Triazines; Vitamins
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Gastric cancer; Pancreatic cancer
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Japan (PO)
  • 02 Jun 2017 Efficacy and adverse events data from a phase III trial in Pancreatic cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 18 Nov 2016 Clinical trials in Gastric cancer (Adjuvant therapy, Neoadjuvant therapy, Late-stage disease) in Japan (PO) (UMIN000024688)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top